CS
PRME icon

Credit Suisse’s Prime Medicine PRME Stock Holding History

Credit Suisse’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,705
Closed -$181K – 3238
2023
Q1 		$181K Buy
14,705
+13,905
+1,738% +$227K ﹤0.01% 3135
2022
Q4 		$14.9K Buy
+800
New +$14.5K ﹤0.01% 3491

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Credit Suisse's PRME Position: Q2 2023 in Review

Credit Suisse sold out of Prime Medicine (PRME) in Q2 2023, closing a stake of 14,705 shares — an estimated $181K sold.

Credit Suisse first reported a position in PRME in Q4 2022 and held it in 2 quarters. The position peaked at $181K in Q1 2023. 79 funds tracked by Wall St. Rank hold PRME as of Q2 2023.

  • Credit Suisse reported no remaining Prime Medicine position as of Q2 2023 after selling out during the quarter.
  • Credit Suisse sold 14,705 Prime Medicine shares in Q2 2023, an estimated $181K.
  • Credit Suisse first reported a position in Prime Medicine in Q4 2022 and held it in 2 quarters.
  • Credit Suisse's Prime Medicine position peaked at $181K in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.